^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AZD3463

    i
    Other names: AZD3463
    Company:
    AstraZeneca
    Drug class:
    ALK inhibitor, IGF-1R inhibitor
    Related drugs:
    4years
    Effects of rapamycin and AZD3463 combination on apoptosis, autophagy, and cell cycle for resistance control in breast cancer. (PubMed, Life Sci)
    In the combination of rapamycin with AZD3463, the expression of CDKN1B, PTEN, FOXO3, and APC genes increases, and the expression of PRKCB and PIK3CG genes decreases. Our results showed that the use of AZD-RAPA reduced the resistance of cancer cells to treatment and it leads cancer cells to apoptosis.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • PTEN (Phosphatase and tensin homolog) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • FOXO3 (Forkhead box O3) • CDKN1B (Cyclin dependent kinase inhibitor 1B)
    |
    PTEN expression • CDKN1B expression
    |
    sirolimus • AZD3463